F2G to use $70m financing to advance olorofilm
British antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm.
Sosei announces $1.2bn R&D collaboration with Abbvie
Sosei Heptares and AbbVie have inked a multi-target licence option drug discovery agreement in neurology.
UK-Spanish team to optimise efficacy of microbial production processes
Researchers have presented a novel method to promote biofilm formation and thus to increase efficiency of biocatalysis in biotech production.
InflaRX set to file for MAA for vilobelimab
InflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company’s treatment for critically ill COVID-19 patients.
New antibody cocktail might fight all corona variants
A nasal antibody cocktail binding to the conserved S2 stalk region of SARS-COV-2 might end the corona pandemic.
Ring exchange at Roche’s top executive level
Schwan follows Franz, Schinecker follows Schwan.
French-German Novasep-PharmaZell Group invests EUR7.3M at Mourenx site
This new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used to treat cancer.
Oxford Science Enterprises raised a further £250 million ($300 million) in funding
Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million (>$1 billion) since inception in 2015 according to the company´s statement.
Swedish Bioinvent issues shares worth SEK299m (USD28m)
BioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including new investors such as AXA Investment Managers and a US institutional investor and the existing shareholders Forbion, HBM Healthcare Investments, Redmile Group, Invus, the Fourth National Swedish Pension Fund and Swedbank Robur Fonder, with demand for the new shares exceeding the size of the planned volume.
Immunocore has a sip with USD140m private placement
Immunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.